FDA Reopens Comment Period on Biological Products Development Workshop

Article

FDA Reopens Comment Period on Biological Products Development Workshop

The US Food and Drug Administration (Rockville, MD, www.fda.gov) has reopened the comment period for the notice of a public workshop dedicated to the development and availability of new biological products. Interested persons now have until 27 January 2006 to submit comments to the workshop entitled “From Concept to Consumer: Center for Biologics Evaluation and Research Working with Stakeholders on Scientific Opportunities for Facilitating Development of Vaccines, Blood and Blood Products, and Cellular, Tissue, and Gene Therapies,” which was held 7 October 2004.

The objective of the workshop was to provide an opportunity for attendees to discuss the development of innovative scientific knowledge and tools to facilitate the development and availability of new biological products, including vaccines, blood and blood products, and cellular, tissue, and gene therapies (Fed. Register 70 [17], 3935 [27 January 2005]).

The notice of public workshop and request for comments was originally published in the 31 August 2004 edition of the Federal Register. At that time, the agency provided only a 23-day period for submitting comments on the workshop’s topic. The January 2006 deadline now allows interested persons additional time for submitting comments and gathering information. Electronic comments specifying Docket Number 2004N-0366 can be submitted to http://www.fda.gov/dockets/ecomments.

–Maribel Rios



Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes